SEC Form 4 · accession 0001055726-19-000007

INOVIO PHARMACEUTICALS, INC. · INO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Mar 5, 2019

Accepted (ET)

Mar 7, 2019 · 5:09 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001055726

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Mar 5, 2019	M	120,100	—	A	2,428,594	D
Common Stock	Mar 5, 2019	F	34,139	$3.61	D	2,394,455	D
Common Stock	holding	—	—		—	1,750,000	I	By Family Limited Partnership
Common Stock	holding	—	—		—	33,563	I	By Daughter: EK
Common Stock	holding	—	—		—	33,775	I	By Son: JK1
Common Stock	holding	—	—		—	5,975	I	By Spouse
Common Stock	holding	—	—		—	33,533	I	By Son: JK2

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Unit^F1	—	Mar 5, 2019	M	120,100	D	—	—	Common Stock	120,100	240,200	D

F1Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 360,300 restricted stock units is as follows: 120,100 shares vested on March 5, 2019; 120,100 shares will vest on March 5, 2020; 120,100 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.
F2The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.